https://www.selleckchem.com/pr....oducts/cenicriviroc.
Previously unscreened women with no comorbid conditions and no history of screening could undergo an initial screening through 90 years, whereas unscreened males could undergo initial screening through 88 years, before this balance is reached. As screening adherence improved or as comorbidities increased, the optimal age to stop screening decreased to a point that, regardless of sex, individuals with severe comorbidities and perfect screening history should stop screening at age 66 years or younger. Conclusions Based on the harm-be
Like
Comment
Share
